Back to Longevity & Metrics
Mitocondria con ATP synthase y cadena de transporte de electrones — Ubiquinol CoQ10

Ubiquinol CoQ10 — Mitochondria and Cardiovascular

CoQ10 in its reduced form (ubiquinol) — the only form bioavailable directly without requiring enzymatic conversion. 100 mg per softgel. Essential for mitochondrial ATP production and for chronic statin users. 60 softgels (approximately 60 days). Protocol: with a high-fat meal, 8–12 weeks with monitoring of energy or cardiac function biomarkers.

Where to buy

Compare
Category: ,
Tags: , , , , , ,

Quick summary

The coenzyme Q10 (CoQ10) It is essential for the mitochondrial electron transport chain: without it, there is no ATP production. It exists in two forms: ubiquinone (rusty) and ubiquinol (reduced and bioavailable). After age 40, the enzymatic conversion of ubiquinone to ubiquinol drops dramatically; statins directly inhibit its endogenous synthesis by blocking HMG-CoA reductase. The reduced form is 3–8× more bioavailable in adults over 40.

Mechanism of action

  • ATP production: electron transporter between mitochondrial complexes I/II and III; without CoQ10 oxidative phosphorylation collapses.
  • Lipophilic membrane antioxidant: It protects mitochondrial phospholipids and LDL lipoproteins from peroxidation.
  • Endothelial function: It improves nitric oxide (NO)-dependent vasodilation in peripheral arteries.
  • Vitamin E regeneration: It reduces α-tocopheroxyl to active α-tocopherol, expanding the antioxidant network.
  • Ubiquinol form: 3–8× more bioavailable than ubiquinone in adults >40 years, at which point endogenous enzyme conversion decreases.

Clinical evidence

Robust evidence

  • Heart failure: Mortensen SA et al. (JACC Heart Failure, 2014, Q-SYMBIO trial) — reduction of cardiovascular mortality in class III–IV HF.
  • Statin-induced myalgia: Case G et al. (Am J Cardiol, 2007) — reduction of muscle pain in patients treated with statins.
  • Superior bioavailability of ubiquinol: Hosoe K et al. (Regul Toxicol Pharmacol, 2007).

Plausible / suggested

  • Improvement of ejection fraction in advanced HF (Langsjoen P, Biofactors, 2008).
  • Reduction in frequent migraine (small studies).
  • Support in male infertility (seminal parameters).
  • Improvement of subjective fatigue in fibromyalgia and chronic fatigue syndrome.

Speculative / preclinical

  • Neuroprotection in Parkinson's disease (mixed results in humans).
  • Modulation of mitochondrial senescence.

Molecular form and bioavailability

He ubiquinol (Reduced CoQ10) requires a specialized manufacturing process to maintain stability. The clinical reference raw material is Kaneka Ubiquinol™, produced by fermentation with yeasts and patented to prevent oxidation.

Bioavailability is 3–8× superior to conventional ubiquinone, especially in those over 40 years of age and in patients with cardiovascular or hepatic dysfunction who have lost conversion capacity. Strictly lipid solubility: requires fatty food For proper absorption. Without fat, bioavailability drops >70%.

Limitations and what it DOES NOT do

  • It is not a nootropicThe effect is energetic/cardiovascular, not directly cognitive.
  • It does not reverse established structural heart damage—it supports residual function.
  • The effect is slow and cumulative; it is not felt for hours.
  • In healthy young adults without specific stressors, the marginal benefit is low.

Target population

  • Adults >40 years with subjective decline in energy or aerobic capacity.
  • Patients on chronic statin therapy (documented drug depletion).
  • Moderate heart failure (always as a complement, not a substitute for treatment).
  • Master/veteran athletes with declining performance.
  • Recurrent migraine as a preventative measure.
Warning: This content is for informational and educational purposes only, based on available scientific literature. It does not constitute medical advice and does not replace consultation with a healthcare professional. Claims regarding supplements have not been evaluated by the FDA or COFEPRIS to diagnose, treat, cure, or prevent any disease. Consult your doctor before starting any supplement, especially if you are pregnant, breastfeeding, under 18 years of age, or taking medication.

Elite products, audited without intermediaries.

Every molecule in the Arsenal undergoes rigorous editorial review before making it here. We don't sell advertising, we don't accept products in exchange for reviews, and we have no commercial ties to any manufacturers. What you see listed is what an independent team deemed defensible in light of the available clinical literature—and only high-end products are included.

The process includes:

  • Systematic review of human clinical evidence (meta-analysis, RCTs and mechanistic studies).
  • Traceable raw materials, cGMP manufacturing, and third-party testing with CoA per batch.
  • Automatic disposal of sub-clinical doses, “proprietary blends” that conceal unnecessary quantities and excipients.
  • Verification of purity, oxidative stability and regulatory consistency between batches.

Depending on the country you're reading from, several different presentations may meet all the criteria. Any product we recommend below—regardless of the brand or specific format available in your region—has passed through the same filter. What doesn't change is the molecule, the dose and the quality criteria.

The molecule: ubiquinol (reduced CoQ10)

The inclusion criterion is the reduced form (ubiquinol) with characterized raw materials and a lipid carrier. We ruled out conventional ubiquinone for those over 40 years of age because endogenous conversion declines with age, reducing the actual delivery to the tissue.

Audit criteria

  • Reduced form (ubiquinol): Check label — ”CoQ10” without specifying form is usually ubiquinone, which is less bioavailable.
  • Kaneka Ubiquinol™ raw material: the only ubiquinol with robust clinical literature and proven stability.
  • Lipid vehicle: softgel with oil (sunflower, MCT or olive) — dry ubiquinol oxidizes quickly.
  • Useful dose: ≥100 mg of ubiquinol per daily dose; 200 mg for cardiovascular support or statins.
  • cGMP Manufacturing: FDA audited facilities or equivalent.
  • Third-party tests: Batch CoA available on demand.

Commercial flags we discard

  • “CoQ10” without specifying whether it is ubiquinol or ubiquinone —in people over 40 the difference is relevant.
  • Dry powder capsules (not softgel): ubiquinol oxidizes and loses activity.
  • Subclinical doses (30–50 mg) presented as “advanced formula”.
  • Generic raw materials without traceability of origin Kaneka.

How to read this protocol.

What follows is a general guide based on the available clinical evidence for this molecule. It is a reasonable starting point, but The information that always prevails is that on the packaging of the specific product you purchase.Dosage, frequency, and method of administration should follow the manufacturer's instructions on the label, as they may vary depending on the presentation, concentration, and region. If you have any questions, consult a healthcare professional.

Dose

  • Standard dose: 100 mg/day with the main meal (with fat).
  • Adults on statins: 100–200 mg/day divided.
  • Heart failure (support): 200–300 mg/day divided into 2–3 doses, under medical supervision.
  • Preventive migraine: 100–150 mg/day for 8–12 weeks.

When to take it

  • With the main meal of the day (lunch or dinner), preferably the one with the highest fat content.
  • If divided into 2 feedings, both should be with food.
  • Avoid taking it on an empty stomach: bioavailability drops drastically.

How to take it

  • Swallow the softgel whole with a glass of water.
  • Do not open or chew the softgel — the contents oxidize with light and air.
  • Store in a cool, dark place; refrigeration prolongs shelf life but is not required.

Recommended stack

  • Cardiovascular support: ubiquinol 100 mg + omega-3 (EPA/DHA) 2 g + magnesium 200 mg.
  • Athletes / performance: ubiquinol + creatine + D3 + omega-3.
  • Statin therapy: ubiquinol 100–200 mg + vitamin K2 (MK-7) 100 mcg.

Evaluation window

  • 8–12 weeks for measurable impact.
  • Objective markers: aerobic capacity (VO2max if available), blood pressure, ejection fraction by echo if applicable.
  • Subjective: fatigue, post-exertion recovery, clarity of sustained thought.

Flags (when not to use them)

  • Anticoagulants (warfarin): CoQ10 may reduce the anticoagulant effect; monitor INR.
  • Active chemotherapy: Consult with an oncologist—some regimens require the absence of antioxidants during treatment.
  • Low blood pressure: Monitor blood pressure at the start (mild vasodilator effect).
  • Pregnancy / breastfeeding: Limited data; avoid unless medically advised.
  • Scheduled surgery: discontinue 2 weeks prior (mild antiplatelet effect).

Reviews

There are no reviews yet

Only logged in customers who have purchased this product may leave a review.

Related products

Select at least 2 products
to compare